Rostafuroxin (PST 2238)

Selective antagonist of endogenous ouabain, antihypertensive agent CAS# 156722-18-8

Rostafuroxin (PST 2238)

Catalog No. BCC6431----Order now to get a substantial discount!

Product Name & Size Price Stock
Rostafuroxin (PST 2238): 5mg $81 In Stock
Rostafuroxin (PST 2238): 10mg Please Inquire In Stock
Rostafuroxin (PST 2238): 20mg Please Inquire Please Inquire
Rostafuroxin (PST 2238): 50mg Please Inquire Please Inquire
Rostafuroxin (PST 2238): 100mg Please Inquire Please Inquire
Rostafuroxin (PST 2238): 200mg Please Inquire Please Inquire
Rostafuroxin (PST 2238): 500mg Please Inquire Please Inquire
Rostafuroxin (PST 2238): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Rostafuroxin (PST 2238)

Number of papers citing our products

Chemical structure

Rostafuroxin (PST 2238)

3D structure

Chemical Properties of Rostafuroxin (PST 2238)

Cas No. 156722-18-8 SDF Download SDF
PubChem ID 153976 Appearance Powder
Formula C23H34O4 M.Wt 374.51
Type of Compound N/A Storage Desiccate at -20°C
Synonyms PST 2238
Solubility DMSO : ≥ 50 mg/mL (133.51 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (3S,5R,8R,9S,10S,13S,14S,17S)-17-(furan-3-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol
SMILES CC12CCC(CC1CCC3C2CCC4(C3(CCC4(C5=COC=C5)O)O)C)O
Standard InChIKey AEAPORIZZWBIEX-DTBDINHYSA-N
Standard InChI InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Rostafuroxin (PST 2238)

DescriptionNa+/K+ ATPase modulator. Normalizes renal Na+/K+ ATPase pump function in mutant adducin- and endogenous ouabain-dependent forms of hypertension. Reduces blood pressure in Milan hypersensitive rats. Controls mania-like behaviors in Myshkin mice having a Na+/K+ ATPase α3 subunit mutation.

Rostafuroxin (PST 2238) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Rostafuroxin (PST 2238) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Rostafuroxin (PST 2238)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.6702 mL 13.3508 mL 26.7016 mL 53.4031 mL 66.7539 mL
5 mM 0.534 mL 2.6702 mL 5.3403 mL 10.6806 mL 13.3508 mL
10 mM 0.267 mL 1.3351 mL 2.6702 mL 5.3403 mL 6.6754 mL
50 mM 0.0534 mL 0.267 mL 0.534 mL 1.0681 mL 1.3351 mL
100 mM 0.0267 mL 0.1335 mL 0.267 mL 0.534 mL 0.6675 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Rostafuroxin (PST 2238)

Description:

IC50: 2 μM for Na+-K+-ATPase

Two mechanisms are involved in determining the abnormalities of tubular Na+ reabsorption observed in hypertension: the polymorphism of the cytoskeletal protein α-adducin and the increased circulating endogenous ouabain (EO) levels. Both lead to increased activity and expression of the renal Na+-K+ pump, which is the driving force for tubular Na transport. Morphological and functional vascular alterations have also been associated with EO. Rostafuroxin (PST 2238) is a novel oral antihypertensive agent able to selectively antagonize EO, adducin pressor, and molecular effects.

In vitro: At molecular level, in the kidney, Rostafuroxin antagonizes EO by triggering of the Src-epidermal growth factor receptor (EGFr)-dependent signaling pathway leading to renal Na+-K+ pump, and ERK tyrosine phosphorylation and activation. In the vasculature, it normalizes the increased myogenic tone caused by nanomolar ouabain [1].

In vivo: Rostafuroxin reduces blood pressure without affecting heart rate, and restores the normal activity of the renal Na+-K+-ATPase in MHS rats when orally treated at doses from 1 to 100 μg/kg/day. Similarly, NUA rats have their blood pressure normalized by rostafuroxin [1].

Clinical trial: Rostafuroxin has already satisfied safety requirements in phase I studies showing complete tolerability either after single or repeated administrations up to a dose of 10 mg/day, without showing differences in side effect patterns compared with placebo. In two small exploratory studies in patients with mild uncomplicated hypertension, rostafuroxin has been demonstrated to be effective in lowering blood pressure at oral doses from 0.1 to 1 mg/day [1].

Reference:
[1] Ferrari P, Ferrandi M, Valentini G, Bianchi G.  Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35.

Featured Products
New Products
 

References on Rostafuroxin (PST 2238)

Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension.[Pubmed:17535730]

Cell Mol Biol (Noisy-le-grand). 2006 Dec 30;52(8):15-8.

Experimental and clinical evidence indicates that Endogenous Ouabain (EO) and Adducin polymorphism play a pathogenetic role in hypertension and related organ complications. These effects occur through a complex interaction of genetic molecular mechanisms regulating renal sodium reabsorption and vascular function. The activation of a Na-K ATPase-Src-EGFr-ERK signaling pathway within the restricted membrane subdomains of caveolae by Ouabain has been associated to hypertension and cardiac remodeling. Rostafuroxin (PST 2238) is a novel anti-hypertensive compound able to selectively antagonize EO/Ouabain and Adducin hypertensive effect and Ouabain-induced cardiac hypertrophy in rats. Studies have been conducted in vivo and in a cell-free system to prove that Rostafuroxin exerts its antihypertensive and antihypertrophic effects by antagonizing the Src-dependent signaling triggered by Ouabain. At the vascular level, Rostafuroxin antagonizes the Ouabain-mediated increase of myogenic vascular tone. This peculiar and novel mechanism of action, together with a good tolerability and efficacy both in animal models and hypertensive patients, make Rostafuroxin the prototype of a new class of antihypertensive compounds able to antagonize EO/ Ouabain and Adducin molecular effects.

Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension.[Pubmed:20083196]

Biochim Biophys Acta. 2010 Dec;1802(12):1254-8.

An innovative approach to the therapy of essential hypertension (EH) and the related complications has been pursued by our group with the aim of defining specific genetic-molecular mechanisms underlying the disease in sub-sets of patients. This approach is anticipated to have a major effect on the clinical practice, diagnostics and development of new drugs able to selectively target such mechanisms. The final achievement is the definition of biomarkers for identifying patients who more likely should benefit for a given therapy both in terms of efficacy and reduction of the adverse reactions. Among many, two mechanisms have been defined and addressed:Both alterations lead to hypertension, organ hypertrophy, negative vascular remodeling and increased cardiovascular risk by affecting the renal Na(+) handling, through the up-regulation of the Na(+)-K(+) pump and the activation of the Src-dependent signal transduction pathway. A novel antihypertensive agent, rostafuroxin (PST2238), has been selected and developed for its ability to correct the renal Na(+)-K(+) pump abnormalities sustained by the mutant adducin and EO-dependent mechanisms. It is endowed with high potency and efficacy in reducing blood pressure (BP) and preventing organ hypertrophy in animal models representative of both adducin and EO mechanisms. At molecular level, in the kidney, rostafuroxin normalizes the enhanced activity of the Na(+)-K(+) pump induced by mutant adducin and antagonizes the EO triggering of the Src-EGFr-dependent signaling pathway leading to renal Na(+)-K(+) pump and ERK phosphorylation and activation. In the vasculature, it normalizes the increased myogenic tone caused by ouabain. A very high safety ratio and the absence of interaction with other mechanisms involved in BP regulation, together with evidence of high tolerability and efficacy in hypertensive patients indicate rostafuroxin as the first example of a new class of antihypertensive agents designed to antagonize adducin and EO-hypertensive mechanisms. A recently concluded Phase II clinical trial (OASIS) has provided the proof of concept that such a compound is effective in the subset of patients where these two mechanisms are at work.

Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.[Pubmed:16467500]

Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35.

The genetic and environmental heterogeneity of essential hypertension is responsible for the individual variability of antihypertensive therapy. An understanding of the molecular mechanisms underlying hypertension and related organ complications is a key aspect for developing new, effective, and safe antihypertensive agents able to cure the cause of the disease. Two mechanisms, among others, are involved in determining the abnormalities of tubular Na+ reabsorption observed in essential hypertension: the polymorphism of the cytoskeletal protein alpha-adducin and the increased circulating levels of endogenous ouabain (EO). Both lead to increased activity and expression of the renal Na+-K+ pump, the driving force for tubular Na transport. Morphological and functional vascular alterations have also been associated with EO. Rostafuroxin (PST 2238) is a new oral antihypertensive agent able to selectively antagonize EO, adducin pressor, and molecular effects. It is endowed with high potency and efficacy in reducing blood pressure and preventing organ hypertrophy in animal models representative of both adducin and EO mechanisms. At molecular level, in the kidney, Rostafuroxin antagonizes EO triggering of the Src-epidermal growth factor receptor (EGFr)-dependent signaling pathway leading to renal Na+-K+ pump, and ERK tyrosine phosphorylation and activation. In the vasculature, it normalizes the increased myogenic tone caused by nanomolar ouabain. A very high safety ratio and an absence of interaction with other mechanisms involved in blood pressure regulation, together with initial evidence of high tolerability and efficacy in hypertensive patients, indicate Rostafuroxin as the first example of a new class of antihypertensive agents designed to antagonize adducin and EO-hypertensive mechanisms.

Description

Rostafuroxin(PST 2238) is a antihypertensive compound; Na,K-ATPase antognist;displaced [3H]ouabain from the dogkidney Na+,K+-ATPase with IC50 of 1.5 nM.

Keywords:

Rostafuroxin (PST 2238),156722-18-8,PST 2238,Natural Products,Sodium Channel, buy Rostafuroxin (PST 2238) , Rostafuroxin (PST 2238) supplier , purchase Rostafuroxin (PST 2238) , Rostafuroxin (PST 2238) cost , Rostafuroxin (PST 2238) manufacturer , order Rostafuroxin (PST 2238) , high purity Rostafuroxin (PST 2238)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: